S.A. (corporation) | |
Traded as | Euronext: VIRP |
Industry | Animal Health Care |
Founded | 1968 |
Founder | Pierre-Richard Dick |
Headquarters | Carros, France |
Number of locations
|
31 subsidiaries |
Area served
|
More than 100 countries |
Products | Antibiotics, vaccines, dermatology, antiparasitics, dental hygiene... |
Revenue | 773 M€ (2014) |
Number of employees
|
4,350 (2013) |
Website | www |
Virbac is a French company dedicated to animal health. It was founded in 1968 by veterinarian Pierre-Richard Dick.
The company is the 8th largest veterinarian pharmaceutical group with a turnover of 736 million euros in 2013. The company is a limited company with Executive and Supervisory Board. It has been listed on the since 1985 and is member of the SBF 120. The founder's family is the majority shareholder of the company.
Veterinarians Pierre-Richard Dick and Max Rombi founded Virbac (acronym of virology and bacteriology) in 1968 as a veterinary office in the Cap 3000 mall in Nice. The office was sold two years later, after which Dick and Rombi focussed on animal drugs for pets, distinguishing Virbac from large veterinary pharmaceutical companies that specialised in livestock.
At the end of the 1970s, Rombi began the subsidiary Arkovet, from where he developed Arkopharma, specialising in phyto- and nutrition therapy.
Virbac went international in 1983 with the establishment of offices in Egypt and Spain. Subsidiaries followed in the United States of America (1984), Italy, Brazil, Australia, Germany (1987), Mexico (1988), Poland, Japan (1992), and Belgium (1994).
Virbac additionally acquired several companies:
After Pierre-Richard Dick died in a car accident in 1992, his family decided to keep the company.
The company has 4,350 employees and is present in over 100 countries with 30 sales subsidiaries. Its production is located in 10 countries among which France, the US, Mexico, Brazil, Vietnam. It also has seven research and development centers located in the United States, Mexico, Chile, Uruguay, France, Vietnam and Australia. It generates nearly 87% of its revenues outside France.